Search
Research
MEIS proteins as partners of the TLX1/HOX11 oncoproteinAberrant expression of the TLX1/HOX11 proto-oncogene is associated with a significant subset of T-cell acute lymphoblastic leukemias...
News & Events
Finding new treatments for rare brain cancers in infantsThe WA Kids Cancer Centre has secured $1.1 million in funding from the Medical Research Future Fund’s (MRFF) Paediatric Brain Cancer Research Stream 2 to develop more effective and less toxic treatments for rare brain cancers in infants.
News & Events
Adventurers deliver on a promise to help kids with cancerA state of the art 3D molecular imager that will help researchers monitor how brain tumours grow has been delivered to the Telethon Institute.
People
Professor Nick GottardoHead of Paediatric and Adolescent Oncology and Haematology, Perth Children’s Hospital; Co-head, Brain Tumour Research Program, The Kids Research Institute Australia
News & Events
Pioneering new treatments for leukaemia in children with Down syndromeA team of world-leading scientists has secured $5 million in funding from the Leukaemia and Lymphoma Society to advance the fight against leukaemia in children with Down syndrome.
News & Events
The Kids cancer researcher named a Superstar of STEMThe Kids Research Institute Australia brain cancer researcher, Dr Jessica Buck will today join the ranks of a select group of brilliant female scientists.
News & Events
How to win friends and influence people: Cancer researchers talk the talk for big resultsIn the field of cancer research, lobbying efforts by the The Kids Cancer Centre have contributed to major initiatives including Australia’s first personalised medicine program for children with high-risk cancer, and a mission to boost survival rates in brain cancer patients.
Research
IDH-mutant gliomas in children and adolescents - from biology to clinical trialsGliomas account for nearly 30% of all primary central nervous system (CNS) tumors in children and adolescents and young adults (AYA), contributing to significant morbidity and mortality. The updated molecular classification of gliomas defines molecularly diverse subtypes with a spectrum of tumors associated with age-distinct incidence.
Research
Disruption of cotranscriptional splicing suggests that RBM39 is a therapeutic target in acute lymphoblastic leukemiaThere are few options for patients with relapse/refractory B-cell acute lymphoblastic leukemia, thus this is a major area of unmet medical need. Here, we reveal that inclusion of a poison exon in RBM39, which could be induced both by CDK9 or CDK9 independent CMGC (cyclin-dependent kinases, mitogen-activated protein kinases, glycogen synthase kinases, CDC-like kinases) kinase inhibition, is recognized by the nonsense-mediated mRNA decay pathway for degradation.